Logistics of Primary Angioplasty
- 1 June 2002
- journal article
- review article
- Published by S. Karger AG in Heart Drug
- Vol. 2 (6) , 321-325
- https://doi.org/10.1159/000069667
Abstract
Aims: After many years of debate, primary angioplasty has emerged as the best reperfusion treatment for acute myocardial infarction (AMI). However, the scarce availability of qualified invasive facilities remains the major limitation of this strategy compared to the simple intravenous administration of effective lytic agents. Methods: To enlarge the availability of invasive centers where patients with AMI could be promptly treated with primary angioplasty two lines of action may be pursued; the first is the ‘up-grading’ of low-volume interventional or diagnostic laboratories that do not perform emergency interventions on a regular basis; the second is the creation of a transportation network that enables pre-hospital fibrinolysis and/or the referral of patients from non-invasive centers to high-volume tertiary structures committed to the treatment of AMI at any time. Results: Recent data obtained from randomized studies support both alternatives. In fact, pre-hospital fibrinolysis and transportation or patient transportation without previous fibrinolysis are safe and offer better clinical outcome compared to fibrinolysis started in hospital. Besides, primary angioplasty can also be performed in selected community centers intensively trained that, performing large work volumes, can achieve superior results compared to fibrinolysis started in hospital. Conclusions: The advantages and shortcomings of these two alternatives are commented on in this articleKeywords
This publication has 15 references indexed in Scilit:
- A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: The air primary angioplasty in myocardial infarction studyPublished by Elsevier ,2002
- Clinical characteristics and outcome of patients with early (4h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarctionEuropean Heart Journal, 2002
- Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial InfarctionNew England Journal of Medicine, 2002
- Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trialThe Lancet, 2001
- Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE StudyEuropean Heart Journal, 2000
- Direct percutaneous transluminal coronary angioplasty in acute myocardial infarction. Predictors of short-term outcome and the impact of coronary stentingEuropean Heart Journal, 1998
- Clinical Experience With Primary Percutaneous Transluminal Coronary Angioplasty Compared With Alteplase (Recombinant Tissue-Type Plasminogen Activator) in Patients With Acute Myocardial InfarctionJournal of the American College of Cardiology, 1998
- Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative reviewJAMA, 1997
- Does Low Individual Operator Coronary Interventional Procedural Volume Correlate With Worse Institutional Procedural Outcome?Journal of the American College of Cardiology, 1997
- A Clinical Trial Comparing Primary Coronary Angioplasty with Tissue Plasminogen Activator for Acute Myocardial InfarctionNew England Journal of Medicine, 1997